Show simple item record

dc.contributor.authorRossey, Iebe
dc.contributor.authorGilman, Morgan S A
dc.contributor.authorKabeche, Stephanie C
dc.contributor.authorSedeyn, Koen
dc.contributor.authorWrapp, Daniel
dc.contributor.authorKanekiyo, Masaru
dc.contributor.authorChen, Man
dc.contributor.authorSpitaels, Jan
dc.contributor.authorGraham, Barney S
dc.contributor.authorSchepens, Bert
dc.contributor.authorMcLellan, Jason S
dc.contributor.authorSaelens, Xavier
dc.contributor.authorMas-Lloret, Vicente 
dc.contributor.authorMelero, Jose Antonio 
dc.date.accessioned2020-06-16T07:34:00Z
dc.date.available2020-06-16T07:34:00Z
dc.date.issued2017
dc.identifier.citationNat Commun . 2017 Feb 13;8:14158.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/10416
dc.description.abstractHuman respiratory syncytial virus (RSV) is the main cause of lower respiratory tract infections in young children. The RSV fusion protein (F) is highly conserved and is the only viral membrane protein that is essential for infection. The prefusion conformation of RSV F is considered the most relevant target for antiviral strategies because it is the fusion-competent form of the protein and the primary target of neutralizing activity present in human serum. Here, we describe two llama-derived single-domain antibodies (VHHs) that have potent RSV-neutralizing activity and bind selectively to prefusion RSV F with picomolar affinity. Crystal structures of these VHHs in complex with prefusion F show that they recognize a conserved cavity formed by two F protomers. In addition, the VHHs prevent RSV replication and lung infiltration of inflammatory monocytes and T cells in RSV-challenged mice. These prefusion F-specific VHHs represent promising antiviral agents against RSV.es_ES
dc.description.sponsorshipWe thank Amanda Gonçalves and Eef Parthoens from VIB Bio Imaging Core, Liesbeth Vande Ginste, Lien Van Hoecke, Soraya Van Cauwenberghe and Emilie Shipman for excellent technical assistance and Dr Florencia Linéro for providing the control VHH. This study was supported by IWT-Vlaanderen (Ph.D. student fellowship to I.R.), National Institute of General Medical Sciences of the National Institutes of Health award T32GM008704 (M.S.A.G.) and P20GM113132 (J.S.M.), FWO-Vlaanderen (Postdoctoral fellowship to B.S.), Ghent University Special Research Grant BOF12/GOA/014, Interuniversity Attraction Poles programme (IAP7, BELVIR), VIB and Mineco (Spain) Grant SAF2015-67033-R (J.A.M.). Results shown in this report are derived in part from work performed at Argonne National Laboratory, Structural Biology Center at the Advanced Photon Source. Argonne is operated by UChicago Argonne, LLC, for the U.S. Department of Energy, Office of Biological and Environmental Research under contract DE-AC02-06CH11357. Data in this report were also obtained at GM/CA@APS, which has been funded in whole or in part with Federal funds from the National Cancer Institute (ACB-12002) and the National Institute of General Medical Sciences (AGM-12006).es_ES
dc.language.isoenges_ES
dc.publisherNature Publishing Group es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAnimals es_ES
dc.subject.meshAntibodies, Neutralizing es_ES
dc.subject.meshCamelids, New World es_ES
dc.subject.meshChlorocebus aethiops es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMice es_ES
dc.subject.meshMonocytes es_ES
dc.subject.meshProtein Binding es_ES
dc.subject.meshRespiratory Syncytial Virus Infections es_ES
dc.subject.meshRespiratory Syncytial Virus, Human es_ES
dc.subject.meshSingle-Domain Antibodies es_ES
dc.subject.meshT-Lymphocytes es_ES
dc.subject.meshVero Cells es_ES
dc.subject.meshViral Fusion Proteins es_ES
dc.subject.meshVirus Replication es_ES
dc.titlePotent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID28194013es_ES
dc.format.volume8es_ES
dc.format.page14158es_ES
dc.identifier.doi10.1038/ncomms14158es_ES
dc.contributor.funderNational Institutes of Health (Estados Unidos) 
dc.contributor.funderMinisterio de Economía y Competitividad (España) 
dc.contributor.funderNIH - National Cancer Institute (NCI) (Estados Unidos) 
dc.contributor.funderNIH - National Institute of General Medical Sciences (NIGMS) (Estados Unidos) 
dc.description.peerreviewedes_ES
dc.identifier.e-issn2041-1723es_ES
dc.relation.publisherversionhttps://doi.org/10.1038/ncomms14158es_ES
dc.identifier.journalNature communicationses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/T32GM008704es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/BOF12/GOA/014es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/SAF2015-67033-Res_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/DE-AC02-06CH11357es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/ACB-12002es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/AGM-12006es_ES
dc.rights.accessRightsopen accesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional